首页 > 

big fish casino how to get lots of chips

2025-01-25
A look at Delaware County high school football on this weekend in years past... 30 Years Ago Marty Brown gains 281 yards on 16 carries and has scoring runs of 39, 15, 48 and 58 yards and Pat Kane runs for a touchdown and catches a TD pass from Chris Fox as Springfield rolls past Radnor, 57-0, to finish 9-0 in the Central League ... Brian Morris runs for three touchdowns, John Tinney throws three scoring passes and Steve Carroll has three interceptions in Ridley’s 35-7 win over Strath Haven ... Jonathan Bystrek scores on an 86-yard kickoff return and a 16-yard run and Mike Mitros tosses TD passes to Chris Hemmert and Anthony Becht as Monsignor Bonner beats Bishop McDevitt, 34-14, in a Catholic League semifinal playoff game ... Defensive end Pete Sousa runs 40 yards with a fumble for Archbishop Carroll’s first score in a 12-9 Catholic League semifinal win over Father Judge. 40 Years Ago Rusty Richter gets two touchdowns, one a 55-yard punt return, and Brian Thompson scores on a 30-yard interception return as Ridley completes a 9-0 Central League season by beating Springfield, 25-0 ... Mike Griffin runs for three TDs and Bryan Carroll scores on a 15-yard run with a blocked punt in Strath Haven’s 34-7 win over Penncrest ... Defensive lineman Barney DelSordo recovers a fumble for the touchdown that gives Garnet Valley a 12-9 decision over Interboro ... Tom Colvin, Bill Horan and Mike Meiswich get TDs and Ed Monaghan and Pete Ruggieri lead the defense in Monsignor Bonner’s 19-3 Catholic League playoff win over West Catholic ... Mike Joyce has a scoring run, Don O’Brien kicks a 30-yard field goal and Burt Grossman has a sack for a safety as Archbishop Carroll defeats Cardinal O’Hara, 12-7, in a Catholic League playoff game. 50 Years Ago Joe Keefer runs for a touchdown after three Mike Bailey to Mike Saska completions account for 55 yards and Vince LaSorsa, Mike McBride and Al Conicella lead the defense as Archbishop Carroll defeats West Catholic, 7-0, to win the Catholic League Southern Division playoff title ... Brian Mackrides has a scoring run and throws a scoring pass in Springfield’s 35-0 win over Marple Newtown ... Larry Jackson runs 79 yards with a fumble to score and throws a TD pass to Jerry Benson to help Penncrest to its first victory, 26-20 over Interboro (Charlie Sheckler fumble recovery for a touchdown; Charlie Brehm 76-yard kickoff return TD) ... Dean Johnson tosses three scoring passes, two to Willie Sydnor, in Radnor’s 28-0 win over Lower Merion. 20 Years Ago John Dempsey gains 183 yards on six carries, including touchdown runs of 68, 58 and 47 yards, as Cardinal O’Hara defeats Archbishop Ryan, 34-6, in a Catholic League Red Division playoff game ... Greg Kobilka throws a TD pass to Mark Smith in the first half and adds a scoring run in the second half of Archbishop Carroll’s 13-12 Catholic League Blue Division playoff loss to West Catholic ... Steve Jones runs for a touchdown in the first minute of the fourth quarter to help Penn Wood snap a 10-game losing streak with an 8-3 win over Harriton. 10 Years Ago Nasir Adderley scores on punt returns of 54 and 47 yards to help Great Valley to a 21-0 District 1 Class 3A championship game victory over Springfield (12-1), which gets interceptions by Ricky Sterling and Alex Masino and a quarterback sack from Brian Layden ... Nazim Trammell-Wells, Sterling Williams and Zeph Ellis (80-yarder) run for touchdowns, but Delco Christian drops a 29-22 PIAA Class A playoff decision to St. Pius X (Tre Jordan two TD runs, two scoring passes).CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.big fish casino how to get lots of chips

“Make Good: The Post Office Scandal,” a musical performance of one of the United Kingdom’s most devastating miscarriages of justice, just wrapped up its tour of the English countryside. It told the story of 983 British Post Office managers falsely accused of theft, ruining their reputations and, for some, landing them in jail. Later, it was revealed that accounting discrepancies due to computer error were to blame. “Make Good” highlights how news stories can sometimes be told – and better told – in an entertainment format. When “Mr Bates vs The Post Office,” a TV dramatization of the scandal, aired a year ago, many viewers were outraged that they had not previously heard of the case and blamed the U.K.’s mainstream media for failing in their work. Journalists responded that they had indeed followed the case, some for more than a decade. Audiences, they said, had simply not been listening. “A complete story taken in one sitting has an impact on you in the way that 3,000 snippets of news through your social media or radio or television just can’t,” says Jeanie O’Hare, writer of “Make Good.” “I think that’s the way our imaginations work.” It was a stage show that defied the norm, re-creating one of the United Kingdom’s most devastating miscarriages of justice. And “Make Good: The Post Office Scandal” did it as a musical. There were choreographed dance numbers, power ballads, and pounding rock riffs. But as this show toured sleepy village halls across England, it also told the story of 983 British Post Office managers falsely accused of theft : allegations that destroyed their reputations, livelihoods, and, for some, landed them in jail. Later, it was revealed that accounting discrepancies due to errors in the Post Office’s Horizon computer system were to blame – a fact that the 364-year-old institution repeatedly tried to cover up. “Make Good,” which wrapped up in early December after six weeks on the road, highlights how news stories can sometimes be told – and better told – in an entertainment format. Like the drama series about the Post Office scandal aired a year ago , “Mr Bates vs The Post Office,” dramatizations of the news can often draw more attention to an event. They can also build public pressure for injustices to be addressed. And that can happen even when the media did due diligence in covering the news when it happened. Entertainment just seems to hit differently. “Theater is the best empathy machine we’ve ever built. You start to think about someone else’s worldview, start to stand in their shoes,” says Jeanie O’Hare, writer of “Make Good.” “I do think it makes stories cut through.” Watching the musical on a winter’s night in Marsden, a village tucked among the hills of northern England, many in the audience are visibly moved. There are four actors on stage, but also live musicians and a community choir; the room is crowded. As the show builds to a finale, the sound pushes in from all sides. For Ms. O’Hare, a former chair of playwriting at the David Geffen School of Drama at Yale University, it was the scandal’s emotional punch that spurred her imagination. She created the show alongside composer Jim Fortune and theater companies New Perspectives and Pentabus, troupes that specialize in reaching the kinds of rural locations where local Post Offices act as cornerstones of the community. She was not alone in seeing the scandal’s storytelling potential. In December 2023, ITV, one of the U.K.’s major TV channels, released “Mr Bates vs The Post Office.” It received widespread acclaim from audiences and critics alike. But the series also revealed an uneasy disconnect between the British public and the media. Many viewers were outraged that they had not previously heard of the scandal and blamed the U.K.’s mainstream media for failing in their work. Journalists in turn protested that they had indeed followed the case; specialist publications such as Computer Weekly and the political magazine Private Eye had reported doggedly for more than a decade. Audiences, they said, had simply not been listening. The spat mirrors a deepening social mistrust: According to the Reuters Institute’s “Digital News Report 2024,” just 36% of Britons say they trust the news “most of the time.” That trend pushes productions such as “Make Good” and “Mr Bates vs The Post Office” into the spotlight. And that encourages traditional media – searching for ways to survive in a digital landscape dominated by social media – to seek ways of delivering the same emotional punch as their dramatized counterparts. In the Reuters Institute’s “Journalism, Media, and Technology Trends and Predictions 2024” report , 43% of news publishers said they hoped to offer “more inspirational human stories” to re-engage increasingly news-avoiding audiences. But pitting journalism against an artistic medium such as theater or television does not necessarily make for a fair fight. Even painstakingly researched shows such as “Make Good” can combine characters’ stories to create greater poignancy. They also have the advantage of looking at a story as a whole. The musical spans more than two decades and compresses them into a show that lasts little more than two hours. “A complete story taken in one sitting has an impact on you in the way that 3,000 snippets of news through your social media or radio or television just can’t,” says Ms. O’Hare. “You have to exist in the world of complete narratives. I think that’s the way our imaginations work.” More hope lies in the idea that journalism and more modern, story-driven projects can complement, rather than contend with, each other. While “Make Good” tells the story of the Post Office scandal, it also acts as a starting point for the audience to explore larger, more far-reaching issues, deliberately pushing people to reflect on the growing role of technology in their lives. Former Post Office employee Chris Trousdale was wrongly prosecuted for false accounting, and shared his experiences with both the producers of “Make Good” and “Mr Bates vs The Post Office.” He hopes that the scandal will leave a lasting legacy by prompting businesses and people to be more critical of technology. “It’s not, ‘Oh look, the little British Post Office had a problem.’ This is a warning shot across the bow,” Mr. Trousdale says. “The risk is that something like AI will cause this to happen again,” he says. “And I want everybody in the world to think of the U.K. Post Office. I want them to think, ‘Let’s not prosecute that person. Let’s not fire them. Let’s just investigate a bit further before we act.’” In the meantime, news coverage of the Post Office scandal continues. A yearslong official inquiry into the affair is still ongoing, while those wrongly accused are still waiting for authorities to return the assets of which they were stripped during court proceedings. The battle for compensation is set to be an even longer fight. But for those who felt its devastating effects firsthand, continued public engagement is key. The form it takes is secondary. “The best thing about the musical is you can feel that voice hitting you; it hits a raw nerve,” says Mr. Trousdale. “All of this is about making sure it doesn’t happen again. And if the best way for someone to digest this story and that information is by watching a musical – so be it.”

Author sheds light on James Dean’s secret life in new book

By Katheryn Houghton and Arielle Zionts, KFF Health News (TNS) Tescha Hawley learned that hospital bills from her son’s birth had been sent to debt collectors only when she checked her credit score while attending a home-buying class. The new mom’s plans to buy a house stalled. Hawley said she didn’t owe those thousands of dollars in debts. The federal government did. Hawley, a citizen of the Gros Ventre Tribe, lives on the Fort Belknap Indian Reservation in Montana. The Indian Health Service is a federal agency that provides free health care to Native Americans, but its services are limited by a chronic shortage of funding and staff. Hawley’s local Indian Health Service hospital wasn’t equipped to deliver babies. But she said staff there agreed that the agency would pay for her care at a privately owned hospital more than an hour away. That arrangement came through the Purchased/Referred Care program, which pays for services Native Americans can’t get through an agency-funded clinic or hospital. Federal law stresses that patients approved for the program aren’t responsible for any of the costs. But tribal leaders, health officials, and a new federal report say patients are routinely billed anyway as a result of backlogs or mistakes from the Indian Health Service, financial middlemen, hospitals, and clinics. The financial consequences for patients can last years. Those sent to collections can face damaged credit scores, which can prevent them from securing loans or require them to pay higher interest rates. The December report , by the federal Consumer Financial Protection Bureau, found these long-standing problems contribute to people in Native American-majority communities being nearly twice as likely to have medical debt in collections compared with the national average. And their amount of medical debt is significantly higher. The report found the program is often late to pay bills. In some cases, hospitals or collection agencies hound tribal citizens for more money after bills are paid. Hawley’s son was born in 2003. She had to wait another year to buy a home, as she struggled to pay off the debt. It took seven years for it to drop from her credit report. “I don’t think a person ever recovers from debt,” Hawley said. Hawley, a cancer survivor, still must navigate the referral program. In 2024 alone, she received two notices from clinics about overdue bills. Frank White Clay, chairman of the Crow Tribe in Montana, testified about the impact of wrongful billing during a U.S. House committee hearing in April. He shared stories of veterans rejected for home loans, elders whose Social Security benefits were reduced, and students denied college loans and federal aid. “Some of the most vulnerable people are being harassed daily by debt collectors,” White Clay said. No one is immune from the risk. A high-ranking Indian Health Service official learned during her job’s background check that her credit report contained referred-care debt, the federal report found. Native Americans face disproportionately high rates of poverty and disease , which researchers link to limited access to health care and the ongoing impact of racist federal policies . White Clay is among many who say problems with the referred-care program are an example of the U.S. government violating treaties that promised to provide for the health and welfare of tribes in return for their land. The chairman’s testimony came during a hearing on the Purchased and Referred Care Improvement Act, which would require the Indian Health Service to create a reimbursement process for patients who were wrongfully billed. Committee members approved the bill in November and sent it for consideration by the full House. A second federal bill, the Protecting Native Americans’ Credit Act , would prevent debt like Hawley’s from affecting patients’ credit scores. The bipartisan bill hadn’t had a hearing by mid-December. The exact number of people wrongfully billed isn’t clear, but the Indian Health Service has acknowledged it has work to do. The agency is developing a dashboard to help workers track referrals and to speed up bill processing, spokesperson Brendan White said. It’s also trying to hire more referred-care staff, to address vacancy rates of more than 30%. Officials say problems with the program also stem from outside health providers that don’t follow the rules. Melanie Egorin, an assistant secretary at the U.S. Department of Health and Human Services, said at the hearing that the proposed legislation doesn’t include consequences for “bad actors” — health facilities that repeatedly bill patients when they shouldn’t. “The lack of enforcement is definitely a challenge,” she said. But tribal leaders warned that penalties could backfire. Related Articles Health | How America lost control of the bird flu, setting the stage for another pandemic Health | How to kick back, relax and embrace a less-than-perfect holiday Health | New childhood leukemia protocol is ‘tremendous win’ Health | For some FSA dollars, it’s use it or lose it at year’s end Health | Norovirus is rampant. Blame oysters, cruise ships and holiday travel White Clay told lawmakers that some clinics already refuse to see patients if the Indian Health Service hasn’t paid for their previous appointments. He’s worried the threat of penalties would lead to more refusals. If that happens, White Clay said, Crow tribal members who already travel hours to access specialty treatment would have to go even farther. The Consumer Financial Protection Bureau report found clinics are already refusing to see any referred-care patients due to the program’s payment problems. The bureau and the Indian Health Service also recently published a letter urging health care providers and debt collectors not to hold patients accountable for program-approved care. White, the Indian Health Service spokesperson, said the agency recently updated the referred-care forms sent to outside hospitals and clinics to include billing instructions and to stress that patients aren’t liable for any out-of-pocket costs. And he said the staff can help patients get reimbursed if they have already paid for services that were supposed to be covered. Joe Bryant, an Indian Health Service official who oversees efforts to improve the referral program, said patients can ask credit bureaus to remove debt from their reports if the agency should have covered their bills. Leaders with the Confederated Tribes of the Colville Reservation in Washington state helped shape the proposed legislation after their citizens were repeatedly harmed by wrongful billing. Tribal Chairman Jarred-Michael Erickson said problems began in 2017, when a regional Indian Health Service office took over the referred-care program from local staff. It “created a domino effect of negative outcomes,” Erickson wrote in a letter to Congress. He said some tribal members whose finances were damaged stopped using the Indian Health Service. Others avoided health care altogether. Responsibility for the Colville Reservation program transferred back to local staff in 2022. Staffers found the billing process hadn’t been completed for thousands of cases, worth an estimated $24 million in medical care, Erickson told lawmakers . Workers are making progress on the backlog and they have explained the rules to outside hospitals and clinics, Erickson said. But he said there are still cases of wrongful billing, such as a tribal member who was sent to collections after receiving a $17,000 bill for chemotherapy that the agency was supposed to pay for. Erickson said the tribe is in the process of taking over its health care facilities instead of having the Indian Health Service run them. He and others who work in Native American health said tribally managed units — which are still funded by the federal agency — tend to have fewer problems with their referred-care programs. For example, they have more oversight over staff and flexibility to create their own payment tracking systems. But some Native Americans oppose tribal management because they feel it releases the federal government from its obligations. Beyond wrongful billing, access to the referred-care program is limited because of underfunding from Congress. The $1 billion budget this year is $9 billion short of the need, according to a committee report by tribal health and government leaders. Donald Warne, a physician and member of the Oglala Sioux Tribe in South Dakota, called the proposed legislation a “band-aid.” He said the ultimate solution is for Congress to fully fund the Indian Health Service, which would reduce the need for the referred-care program. Back in Montana, Hawley said she braces for a fight each time she gets a bill that the referral program was supposed to cover. “I’ve learned not to trust the process,” Hawley said. ©2024 KFF Health News. Distributed by Tribune Content Agency, LLC.Girls basketball roundup: Austin pours in 28 as Spring Garden wins in Champions semifinals

None

Snoop Dogg Reveals Hilarious Deal He Made with Simone BilesThe Department of Energy (DOE) Office of Clean Energy Demonstrations (OCED) opened applications for up to $1.3 billion in funding to catalyze investments in transformative carbon capture, utilization, and storage (CCUS) technologies. This funding—provided by OCED’s Carbon Capture Demonstration Projects Program and the Carbon Capture Large-Scale Pilot Projects Program—will help to catalyze the development and commercialization of carbon capture technologies with significant investments targeting the design, construction, and operation of large-scale point-source carbon capture projects. OCED aims to use this funding to enhance the confidence of commercial entities in adopting CCUS technologies, broaden the market for electricity generation and industrial emitters, and reduce costs to expand the feasibility of CCUS implementation across facilities. This funding aims to help create good-paying jobs, reduce pollution to deliver healthier communities, and ensure America’s global leadership in developing cost-effective emissions reducing technologies for the nation's electricity generation and industrial sectors. Commercial demonstration of advanced carbon capture technologies, integrated with reliable transportation and storage infrastructure, is necessary for the widespread deployment of carbon capture technologies. For this opportunity, OCED plans to fund up to 11 projects across three main topic areas:

Scholar Rock's chief medical officer sells $315,771 in stockTirumala Tirupati Devasthanams (TTD) has implemented a strict ban on making political statements or criticisms regarding Tirumala, following several incidents where political leaders used their visit to the holy site as a platform to criticise rival parties and leaders. In a recent board meeting, TTD unanimously resolved to take action against anyone violating this rule. The ban was implemented from Saturday, with the TTD making it clear that the spiritual climate and sanctity of the hill temple must be maintained by all. Meanwhile, TTD announced the implementation of a special darshan for locals from Tirupati, which will take place on every first Tuesday of the month, starting December 3. Local devotees from Tirupati rural, Tirupati urban, Chandragiri mandal, and Renigunta mandal can obtain tickets at special counters by presenting their Aadhaar cards, as announced by TTD chairman B.R. Naidu.

Healthcare-focused AI startups are raising billions to help improve the US system. AI can help streamline clinical documentation, drug research, and medical billing. This article is part of "Trends in Healthcare," a series about the innovations and industry leaders shaping patient care. Get the inside scoop on today's big stories - delivered daily . Thanks for signing up! Look out for your first newsletter with today's big story in your inbox soon. Thanks for signing up! Access your favorite topics in a personalized feed while you're on the go. Download the app Email address Sign up By clicking “Sign Up”, you agree to receive emails from Business Insider. In addition, you accept Insider's Terms of Service and Privacy Policy . The founder of Suki, a startup that uses artificial intelligence to automate healthcare documents, raised $70 million in funding from investors in a Series D round that was disclosed this past fall. He said it really didn't take that much persuading: With an epidemic of stressed- and burned-out physicians, there was an obvious need for their AI software, he added. "Most of the investor conversations over the last year and a half have been, 'Well, it looks like the market is here,'" said Punit Singh Soni, Suki's founder. "Are you going to be the winner or not?" Suki sells an AI-powered assistant that takes notes during a conversation between patients and clinicians. The notes can be reviewed by the doctor and submitted as an electronic health record. This saves time on administrative tasks and allows physicians more time to take care of patients, a resource that's becoming increasingly limited among healthcare professionals. Surveys have consistently found that doctors and other medical workers are burned out from working in an often overloaded, convoluted, and inefficient system. The US spent $4.8 trillion on healthcare in 2023, according to a January report from the Peter G. Peterson Foundation. The US also spends more per person than nearly all other developed nations, according to a report by the Organization for Economic Co-operation and Development. Despite this, health outcomes were poorer, with Americans facing a lower life expectancy, higher rates of treatable and preventable excess deaths, and less efficient healthcare systems. Cash-strapped hospitals and private practices have lagged behind the financial-services and telecommunications industries in applying newer technologies, but the healthcare industry is increasingly considering artificial intelligence as it contends with high labor costs and a lot of opportunities to automate routine tasks. The pandemic exacerbated these challenges with staffing shortages as overworked doctors and nurses quit the profession. To make healthcare more efficient, AI startups like Suki, Zephyr AI, and Tennr have raised millions with vast promises, including making repetitive tasks like billing and note-taking easier, improving the accuracy of clinical diagnosis, and identifying the right patient population for emerging treatments. But the challenges are vast. The healthcare industry's budget allocations for generative AI are trailing those of many other core industries , such as energy and materials, consumer goods, and retail. Clinical diagnosis will continue to require a human in the loop, so the process can't be fully automated. The healthcare industry is highly regulated, and quite often, venture capitalists will wait for clarity on laws from the federal government before aggressively pushing AI tech advancements forward. A $370 billion bet on boosting the healthcare sector's productivity The consulting firm McKinsey estimates that generative AI can boost productivity for the healthcare, pharmaceuticals, and medical-products industries by as much as $370 billion by accelerating drug research, making clinical documentation easier, speeding up medical billing, and helping doctors make diagnoses. Some big funding rounds announced in 2024 highlight the diverse use cases for AI in the healthcare sector. They include $150 million raised by the clinical-documentation AI startup Abridge in February, the drug-discovery AI startup Xaira Therapeutics bringing in $1 billion before its launch in April, Atropos Health's $33 million Series B in May to help doctors analyze real-world evidence with generative AI, and the medical-billing-automation provider Candid Health raising $29 million in September. Parth Desai, a partner at Flare Capital Partners, has steered investments into healthcare startups such as Photon Health and SmarterDx. He said that healthcare organizations had been dedicating more money to bolster their AI strategies, beginning in late 2022 and accelerating through 2024. That's boosting demand for the tools these startups are developing. There's also less pressure to immediately prove a return on investment, which budget-conscious health systems have closely monitored in the past when allocating dollars for technology. "The thing that we're really studying before making an investment decision is: Do budgets exist today to pay for this technology?" Desai told Business Insider. "Or are they going to exist in a large-enough fashion in the next five to 10 years to support this technology?" Candid Health and Akasa aim to cut costs and automate medical billing One area of particular promise has been medical billing, which could benefit from large language model automation. An LLM could, for example, analyze a large volume of claims in a client's system and accurately match them with insurers' unique billing codes, a process required for repayment to a physician for their services. Hospitals have traditionally relied on human medical coders to hunt down reimbursements from insurers. "The software used to do billing was built a long time ago and basically wasn't kept up to date," Nick Perry, a cofounder and the CEO of Candid Health, said. Malinka Walaliyadde, the CEO of Akasa — another medical-billing-focused AI startup — said the company builds customized LLMs for each healthcare institution it serves. Typically, the aim for these LLMs is to lower costs by lessening the reliance on human medical coders. This often reduces errors in billing and speeds up repayment cycles. "We looked at what are the biggest pain points for health systems," Walaliyadde told BI. He said that Akasa's focus is on developing LLM products for medical coding and simplifying prior authorization, a process that requires approval from a health-plan provider before a patient can receive a treatment. "Those are the ones where you could really move the needle," Walaliyadde said. AI for health screenings George Tomeski, the founder of Helfie AI, is in the middle of pitching investors to raise as much as $200 million in a new round of funding that he hopes to close by the first half of 2025. Tomeski said the funding would help Helfie scale as it exits beta testing for the company's app. The app, also called Helfie, uses a smartphone camera to do medical "checks" that screen for illnesses including COVID-19, tuberculosis, and certain skin conditions. "We're targeting all the health conditions that lead to avoidable mortality," Tomeski said, adding that the app focuses on respiratory and cardiovascular conditions. The intention is for these checks —which can cost as low as $0.20 a person per screen — to serve as a form of preventive care and as an incentive to go see a doctor in person. While some funding is going toward sales and marketing, talent acquisition, and ensuring adherence to regulations around privacy and healthcare data, a large chunk is still being allocated to product development as AI tech advances quickly. Dr. Brigham Hyde, a cofounder and the CEO of Atropos Health, said his latest funding announcement, in May, was timed to coincide with the geared-up launch of ChatRWD, an AI copilot that can answer doctors' questions and quickly churn out published studies based on healthcare data. Hyde said he's keen to bring in big partners this time, including the pharmaceutical giant Merck and the medical-supplies and equipment maker McKesson. But Hyde also had to show some restraint. He said that when Atropos Health moved forward with its Series B rounds, dozens of venture capitalists expressed interest in leading the round. The company was offered up to $100 million but took only one-third of that amount. "I don't always think that's a good idea," Hyde told BI. "As a founder, you want to raise the right amount of money for your business and for the stage you're at." It may be tempting to take more, as many healthcare AI startups — a vast majority still in the seed and early-stage funding rounds — are racing to outmaneuver rivals. Even if the technology is right, it has to get past regulatory approvals and persuade cautious hospitals and health systems to open up their wallets. "You can build as much product as you want, but you can never build a market," Soni of Suki said. "It shows up, or it doesn't show up."Max Verstappen has been stripped of pole position for the Qatar Grand Prix . The Dutchman had topped the timesheets but was under investigation, accused of getting in the way of George Russell . And the stewards have now ruled that he was "driving unnecessarily slowly" in front of the Mercedes man. As a result, Verstappen has been handed a one-place grid penalty. It means Russell inherits pole and will now start ahead of the Red Bull racer. Verstappen has also had one penalty point added to his racing licence. Explaining their decision, the stewards wrote: "Car 1 [Verstappen was on a different preparation strategy to that of Car 63 [Russell]. Car 1 was well outside of the delta and the driver of Car 1 explained he had let Cars 4 [Lando Norris] and 14 [Fernando Alonso] past. "The driver of Car 63 claimed that he had adhered to the delta and did not expect Car 1 to be on the racing line. He stated that if a car was going slow in a high speed corner, it should not be on the racing line. "The stewards regard this case as a complicated one in that clearly Car 1 did not comply with the Race Director’s Event Notes and clearly was driving, in our determination, unnecessarily slowly considering the circumstances. "It was obvious the driver of Car 1 was attempting to cool his tyres. He also could see Car 63 approaching as he looked in his mirror multiple times whilst on the small straight between Turns 11 and 12. "Unusually, this incident occurred when neither car was on a push lap. Had Car 63 been on a push lap, the penalty would have most likely been the usual three-grid position penalty, however in mitigation of penalty, it was obvious that the driver of Car 63 had clear visibility of Car 1 and that neither car was on a push lap." Before the penalty, Verstappen had been left delighted by the pace he found in his Red Bull during qualifying. Earlier in the day, he had struggled to make much progress after losing several places on the opening lap of the sprint. But after securing what he thought would be pole position the Dutchman said: "It's a crazy turnaround. I didn't expect that. Well done to the team for giving me a car that is more connected. We changed some bits on the car, but I never thought it would make such a swing in performance. That is encouraging and I hope it continues into the race." Catch all the action from Formula One on Sky Sports and get exclusive access to races, qualifying and much more for every Grand Prix. From Max Verstappen to Lewis Hamilton, you won't miss a lap on Sky Sports.Charismatic Emma Hayes shows WSL what it has been missing this season | Tom GarryThe North Carolina Teaching Fellows Commission has selected 210 individuals to receive North Carolina Teaching Fellows awards for the Class of 2025 during its early-decision window. The Teaching Fellows program is a competitive, merit-based forgivable loan program providing tuition assistance of up to $10,000 a year for qualified students committed to teaching elementary education, special education, science, technology, engineering, or math in a North Carolina public school. The purpose of the program is to recruit, prepare and support future teachers who attend institutions of higher education in North Carolina. Javascript is required for you to be able to read premium content.

How Crypto Wallets Facilitate B2B TransactionsCarlsquare Advises Boomi on Acquisition of Data Integration Provider Rivery

SAN ANTONIO (AP) — Damari Monsanto's 22 points helped UTSA defeat Southwestern Adventist 117-58 on Thursday. Monsanto added six rebounds for the Roadrunners (6-5). Sky Wicks scored 20 points while shooting 8 for 12, including 4 for 7 from beyond the arc and added eight rebounds and three steals. Amir "Primo" Spears shot 5 of 10 from the field, including 1 for 5 from 3-point range, and went 5 for 6 from the line to finish with 16 points. Domonique Wilkins and Orlando Gooden each scored 19 points for Southwestern Adventist. Jason Garcia had 13 points, four assists and two steals. Monsanto led his team in scoring with 16 points in the first half to help put them up 61-24 at the break. UTSA extended its lead to 87-38 during the second half, fueled by a 13-3 scoring run. Wicks scored a team-high 10 points in the second half. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .

Previous: big fish casino horse racing
Next: big fish casino instagram